Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MRM-3379

Small molecule · developed by Mirum Pharmaceuticals

Phase 2 Most advanced trial

MIRM Developer

2 Registered trials

What is MRM-3379?

MRM-3379 is an investigational small-molecule drug studied in Fragile X Syndrome, Healthy Volunteers.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Mirum Pharmaceuticals, Inc. (MIRM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07209462	Phase 2	Fragile X Syndrome	Recruiting	MIRM
NCT07712718	Phase 1	Healthy Volunteers	Completed	MIRM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fragile X SyndromeHealthy Volunteers

More from Mirum Pharmaceuticals

Cholic Acid FDA approved Maralixibat FDA approved Brelovitug Phase 2/3 Volixibat Phase 2

Sources

ClinicalTrials.gov NCT07712718

Updated Oct 3, 2026. Something wrong or missing? Report it on the MIRM page.

Follow MIRM, the company behind MRM-3379

See MIRM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MIRM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z